Pain Management: New Pharmacological Strategies in the Management of Cancer Pain

References

• World Health Organization Cancer Pain Relief and Palliative Care. World Health Organization, Geneva 1990
   Google Scholar
• Bonica J J. Treatment of cancer pain: Current status and future needs. Advances in Pain Research and Therapy, H L Fields, et al. Raven Press, New York 1985; Vol 9: 589–616
   Google Scholar
• Ventafridda V, Tamburini M, Caraceni A, DeConno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987; 59: 851–856
   Web of Science ®Google Scholar
• Walker V A, Hoskin P J, Hauks G W, et al. Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. J Pain Symptom Management 1988; 3: 145–149
   PubMedGoogle Scholar
• Takeda F. Results of field testing in Japan of the WHO Draft Interim Guidelines on Relief of Cancer Pain. Pain Clin 1986; 1: 83–89
   Google Scholar
• Cleeland C S, Gonin R, Hatfield A K, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med March 3, 1994; 330(9)592–596
   PubMed Web of Science ®Google Scholar
• Von Roenn J H, Cleeland C S, Gonin R, et al. Physician attitudes and practice in cancer pain management: A survey from the Eastern Cooperative Oncology Group. Ann Intern Med 1993; 119: 121–126
   PubMed Web of Science ®Google Scholar
• Drug Treatment of Cancer Pain in a Drug-Oriented Society, C S Hill, H L Fields. Raven Press, New York 1990
   Google Scholar
• Craig A D, Bushnell M C, Zhang E.-T., Blomqvist A. A thalamic nucleus specific for pain and temperature sensation. Nature December, 1994; 372: 22–29, 770–773
   Google Scholar
• Makryannis A. Probes for the cannabinoid sites of action. NIDA Res Monogr 1993; 134: 253–267
   PubMedGoogle Scholar
• Rowe P M. Excitement over orphanin FQ/nocicpetin. Lancet 1996; 347: 606, March 2
   PubMed Web of Science ®Google Scholar
• Stein C. Morphine—A “Local Analgesic.” Pain Clinical Updates. International Association for the Study of Pain. March, 1995; Vol III, Issue 1
   Google Scholar
• Paul D, Bodnar R J, Gistrak M A, Pasternak G W. Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur J Pharmacol 1989; 168: 307–314
   PubMed Web of Science ®Google Scholar
• Paul D, Huang E, Pasternak G W. Autoradiographic localization of kappa opioiad binding sites with [3H]NalBzoh. Neurosci Abstr 1989a; 19: 96.11
   Google Scholar
• Pasternak G W. Selective antagonism of opioid analgesia by a sigma system. J Pharmacol Exp Ther December, 1994; 271(3)1583–1590
   PubMed Web of Science ®Google Scholar
• Raynor K, Kong H, Chen Y, Uasuda K, Yu L, Bell G I. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol February, 1994; 45(2)330–334
   PubMed Web of Science ®Google Scholar
• Hylden J L, Noguchi K, Ruda M A. Neonatal capsaicin treatment attenuates spinal Fos activation and dynorphin gene expression following peripheral tissue inflammation and hyperalgesia. J Neurosci May, 1992; 12(5)1716–1725
   PubMed Web of Science ®Google Scholar
• Dubner R, Ruda M A. Activity dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci 1992; 15: 96–103
   PubMed Web of Science ®Google Scholar
• Tseng L F, Xu J Y, Pieper G M. Increase of nitric oxide production by L-arginine potentates i.c.v. administered beta-endorphine-induced antinociception in the mouse. Eur J Pharmacol March 3, 1992; 212(2–3)301–303
   PubMed Web of Science ®Google Scholar
• Cleary L J, O'Leary F A. Changes in neuronal structure induced by learning. Neurosci Res Center Newslett 1995; 2(1)1–3, Winter
   Google Scholar
• Kelly P T. Mechanisms regulating synaptic plasticity in brain. Neurosci Res Center Newslett 1995; 2(1)4–5, 1, Winter
   Google Scholar
• Portenoy R K. Opioid therapy for chronic nonmalignant pain. Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Progress in Pain Research and Management, H L Fields, J C Liebeskind. IASP Press, Seattle 1994; Vol 1: 247–288
   Google Scholar
• Heller P H, Green P G, Tanner K D, Frederick J-P, . Peripheral neural contributions to inflammation. Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Progress in Pain Research, H L Fields, J C Liebeskind, et al. IASP Press, Seattle 1994; Vol 1: 31–42
   Google Scholar
• Woolf C J, Thompson S WN. The induction and maintenance of central sensitization is dependent on TV-methyl-D-aspartatic acid receptor activation: Implications for pain. Pain March, 1991; 44(3)293–299
   PubMed Web of Science ®Google Scholar
• Bennett G J. Chronic pain due to peripheral nerve damage: An overview. Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Progress in Pain Research, H L Fields, J C Liebeskind. IASP Press, Seattle 1994; Vol 1: 51–60
   Google Scholar
• Price D D, Mao J, Mayer D J. Central neural mechanisms of normal and abnormal pain states. Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Progress in Pain Research, H L Fields, J C Liebeskind. IASP Press, Seattle 1994; Vol 1: 61–84
   Google Scholar
• Fields H L. Relief of unnecessary suffering. Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Progress in Pain Research and Management, H L Fields, J C Liebeskind. IASP Press, Seattle 1994; Vol 1: 1–10
   Google Scholar
• Lemmens H J, Egan T D, Fiset. Pharmacokinetic/dynamic assessment in drug development: Application to the investigational opioid mirfentanil. Anesth Analg June, 1995; 80(6)1206–1211
   PubMed Web of Science ®Google Scholar
• Ossipov M H, Kovelowski C J, Porreca F. The increase in morphine antinociceptive potency produced by carrageenan-induced hind-paw inflammation is blocked by naltrindole, a selective delta-opioid antagonist. Neurosci Lett January 30, 1995; 184(3)173–176
   PubMed Web of Science ®Google Scholar
• Kong H, Raynor K, Yasuda K, Moe S T, Portoghese P S, Bell G I, Reisine T. A single residue, aspartic acid 95, in the delta opioid receptor specifies selective high affinity agonist binding. J Biol Chem November 5, 1993; 268(31)2305–2308
   Google Scholar
• Porecca F, Takemori A E, Sultana M, Portoghese P S, Bown W D, Mosberg H I. Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors. J Pharmacol Exp Ther October, 1992; 263(1)147–152
   PubMed Web of Science ®Google Scholar
• Stein C, Lehrberger K, Yassouridis A, Khoury G. Opioids as novel intra-articular agents in arthritis. Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Progress in Pain Research and Management, H L Fields, J C Liebeskind. IASP Press, Seattle 1994; Vol 1: 289–296
   Google Scholar
• Manfredi P L, Chandler S W, Patt R, Payne R. High-dose epidural infusion of opioids for cancer pain: Cost issues. J Pain Symptom Mgmt February, 1997; 13(2)118–121
   PubMed Web of Science ®Google Scholar
• Krames E S. Intrathecal infusional therapies for intractable pain: Patient management guidelines. J Pain Symptom Mgmt 1993; 8: 36–46
   PubMed Web of Science ®Google Scholar
• Sagen J, Wang H. Optimization of adrenal medullary allograft conditions for pain alleviation. J Neural Transplant Plastic January-March, 1994; 5(1)49–64
   PubMed Web of Science ®Google Scholar
• Joseph J M, Goddard M B, Mills J, Padrun V, Zurn A, Zielinski B, et al. Transplantation of encapsulated bovine chromaffin cells in the sheep subarachnoid space: A preclinical study for the treatment of cancer pain. Cell Transplant September-October, 1994; 3(5)355–364
   PubMed Web of Science ®Google Scholar
• Zimmerman D M, Gidda J S, Cantrell B E, Schoepp D D, Johnson B G, et al. Discovery of a potent, peripherally selective trans-3, 4-dimethyl-4-(3-hydroxyphenyl) piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem July 22, 1994; 37(15)2262–2265
   PubMed Web of Science ®Google Scholar
• Abel S R. Tramadol: An alternative anaglesic to traditional opioids and NSAIDs. J Pharm Care Pain Symptom Control 1995; 3(1)5–29
   Google Scholar
• Dana W J, Weinstein S M. Tramadol: A step-2 analgesic for chronic pain. Cancer Bull November-December, 1995; 47(6)511–514
   Google Scholar
• Chau T T, Lewin A C, Walter T L, Carlson R P, Weichman B M. Evidence for a role of bradykinin in experimental pain models. Agents Actions September, 1991; 34(1–2)235–238
   PubMedGoogle Scholar
• Taiwo Y O, Levine J F. Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. Neuroscience 1991; 44(1)131–135
   PubMed Web of Science ®Google Scholar
• Kyle D J, Burch R M. Recent developments in the understanding of bradykinin receptors. Life Sci 1992; 50(12)829–838
   PubMed Web of Science ®Google Scholar
• Hargreaves K M, Swift J Q, Roszkowski M T, Bowles W, Garry M G, Jackson D L. Pharmacology of peripheral neuropeptide and inflammatory mediator release. Oral Surg Oral Med Oral Pathol October, 1994; 78(4)503–510
   PubMedGoogle Scholar
• Davis A J, Perkins M N. The involvement of bradykinin B1 and B2 receptor mechanism in cytokine-induced mechanical hyperalesia in the rat. Br J Pharmacol September, 1994; 113(1)63–68
   PubMed Web of Science ®Google Scholar
• Moskowitz M A, Cutrer F M. Possible importance of neurogenic inflammation within the meninges to migraine headaches. Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Progress in Pain Research, H L Fields, J C Liebeskind. IASP Press, Seattle 1994; Vol 1: 43–50
   Google Scholar
• Eisenach J C. Overview: First international symposium on alpha 2-adrenergic mechanisms of spinal anesthesia. Regional Anesth July-August, 1993; 189(4)207–212
   Google Scholar
• Vaccarino A L, Marek P, Kest B, Weber E, Keana J F, Liebeskind J C. NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res July 2, 1993; 615(2)331–334
   PubMed Web of Science ®Google Scholar
• Dickenson A H. NMDA receptor antagonists as analgesics. Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Progress in Pain Research, H L Fields, J C Liebeskind. IASP Press, Seattle 1994; Vol 1: 173–187
   Google Scholar
• Tanelian D L, Victory R A. Sodium channel-blocking agents, their use in neuropathic pain conditions. Pain Forum 1995; 4(2)75–80
   Web of Science ®Google Scholar
• Rowbotham M C. Topical analgesic agents. Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Progress in Pain Research, H L Fields, J C Liebeskind. IASP Press, Seattle 1994; Vol 1: 211–228
   Google Scholar
• Cherny L J, Portenoy R. The management of cancer pain. CA Cancer J Clin September-October, 1994; 44(5)263–303
   PubMedGoogle Scholar
• Woolf C J, Chong M S. Preemptive analgesia-Treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg August, 1993; 77(2)362–379
   PubMed Web of Science ®Google Scholar